All In Biotech

NDA 021064 · Lantheus Medcl

Definity

Perflutren · Intravenous · Contrast Agent for Ultrasound Imaging

Novel

Last checked: Nov 20, 2026Latest source record: Mar 1, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2001

Jul 31, 2001

Approved uses

3

Original approval plus efficacy supplements

Registered trials

112

12 Phase 3, 18 recruiting

FAERS reports

5,709

1,899 serious, 116 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: SERIOUS CARDIOPULMONARY REACTIONS Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following perflutren-containing microsphere administration. Most serious reactions occur within 30 minutes of administration. Assess all patients for the presence of any condition that precludes DEFINITY RT administration [see Contraindications (4) ] . Always have resuscitation equipment and trained personnel readily available [see Warnings and Precautions (5.1) ] . WARNING: SERIOUS CARDIOPULMONARY REACTIONS Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following perflutren-containing microsphere administration. Most serious reactions occur within 30 minutes of administration. Assess all patients for the presence of any condition that precludes DEFINITY RT administration ( 4 ). Always have resuscitation...

What it is approved for

From the label in effect Mar 13, 2024.

DEFINITY RT is indicated, after activation, for use in adult and pediatric patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border. DEFINITY RT is an ultrasound contrast agent indicated, after activation, for use in adult and pediatric patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border. ( 1 )

Mechanism: Perflutren lipid microspheres exhibit lower acoustic impedance than blood and enhance the intrinsic backscatter of blood. These physical acoustic properties of activated DEFINITY RT provide contrast enhancement of the left ventricular chamber and aid delineation of the left ventricular endocardial border during echocardiography. In animal models the acoustic properties of activated DEFINITY were established at or below a mechanical index of 0.7 (1.8 MHz frequency). In clinical trials, the majority of the patients were imaged at or below a mechanical index of 0.8.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • DEFINITY · PERFLUTREN 13.04MG/2ML (6.52MG/ML) · INJECTABLE, INTRAVENOUS · Prescription
  • DEFINITY RT · PERFLUTREN 13.04MG/2ML (6.52MG/ML) · INJECTABLE, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Perflutren" as an intervention, any sponsor and status, largest first.

All 112 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • back pain2,424
  • dyspnoea800
  • muscle spasms755
  • pain in extremity504
  • flushing414
  • chest pain403
  • headache382
  • dizziness331
  • urticaria305
  • neck pain304
  • nausea274
  • arthralgia244

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004135
2005195
2006342
2007628
2008279
200935
201031
201115
201223
201329
201420
201564
2016244
2017222
2018187
2019209
2020252
2021251
2022501
2023528
2024509
2025612
2026398

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part B: Definity RT* (Perflutren Lipid Microspheres*) · HCPCS Q9956

2024 spending

$710K

Beneficiaries

6,326

6,640 claims

Per beneficiary

$112

2024 ASP limit $42.34 per unit

View as table
YearSpending
2020$426,133
2021$485,074
2022$512,081
2023$668,279
2024$709,638

Part B: Definity* (Perflutren Lipid Microspheres*) · HCPCS Q9957

2024 spending

$3.8M

Beneficiaries

47,123

49,594 claims

Per beneficiary

$80

2024 ASP limit $42.34 per unit

View as table
YearSpending
2020$3,155,276
2021$3,525,808
2022$3,415,002
2023$3,593,091
2024$3,790,637

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 35 on PubMed

Sponsor: Lantheus Medcl · Also marketed as Definity Rt

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.